A New AI Tool Speeds Up Drug Discovery for Cancer and Beyond

/in /by

Researchers at Tsinghua University in China have created DrugCLIP, an AI system that finds potential new medicines millions of times faster than old methods. Traditional drug discovery uses slow computer simulations to check if a small molecule fits into a protein’s binding pocket, the spot where drugs attach to block or change a protein’s action […]

Read more

Stem Cell Breakthrough Enables Scalable Helper T Cell Therapies

/in , /by

Researchers at the University of British Columbia have achieved a major advance in stem cell engineering by developing a reliable method to produce helper T cells from stem cells in a controlled lab environment. This breakthrough, detailed in the journal Cell Stem Cell, tackles a persistent obstacle in cell therapy production, making treatments more affordable […]

Read more

BrUOG360 Phase Ib/II Trial: Copanlisib Plus Rucaparib for mCRPC With HRD

/in , , , /by

Copanlisib combined with rucaparib demonstrates tolerability and early signals of activity in metastatic castration-resistant prostate cancer (mCRPC), according to results from the BrUOG360 phase Ib/II trial published in late 2025. ​Metastatic castration-resistant prostate cancer with homologous recombination deficiency (HRD) responds to PARP inhibitors like rucaparib, but many patients develop resistance through alternative DNA repair pathways. […]

Read more

Deciparticle Everolimus: Reviving mTOR Inhibition for Neuroendocrine Prostate Cancer?

/in , /by

Sapu-003, a nanoparticle-formulated version of everolimus delivered via a new platform (Deciparticle) has received approval for first-in-human Phase 1 testing in breast cancer patients, representing a major advance in intravenous oncology drug delivery. Unlike the standard oral everolimus tablet, which achieves only 10-20% bioavailability due to extensive first-pass metabolism and gastrointestinal degradation, the Deciparticle platform […]

Read more

ADI-212: Immune Cells Engineered to Beat Advanced Prostate Cancer

/in , /by

ADI-212 is a new type of immune cell therapy made from gamma delta T cells, the kind of immune cells that naturally go after tumors. These cells are specially engineered to attack PSMA-positive metastatic castration-resistant prostate cancer. The therapy has two smart upgrades. First, it carries a special version of IL-12, a powerful immune signal, […]

Read more

PSMA-1-DOTA: A New Ligand to Make Prostate Cancer Radioligand Therapy More Targeted

/in , /by

PSMA-targeted radioligand therapy (RLT) has transformed treatment for end-stage prostate cancer, offering strong tumor control in patients who have exhausted other options. However, these therapies frequently cause severe salivary gland damage, leading to debilitating dry mouth that often forces patients to stop treatment early. To overcome this, researchers at Case Western Reserve University developed PSMA-1-DOTA, […]

Read more

PT-112 Update: Phase 2 Biomarker Findings Pave Way for Phase 3 in End-Stage Prostate Cancer

/in , , /by

Since FDA cleared PT-112 for a pivotal phase 3 trial in May 2025 (we talked about it here) following a successful end-of-phase-2 meeting, fresh insights illuminate why this novel platinum-based agent merits excitement for late-line metastatic castration-resistant prostate cancer (mCRPC). PT-112 stands apart from traditional platinums: its pyrophosphate structure drives osteotropism (high bone accumulation alongside […]

Read more

Dual FOXA1/FOXA2 Targeting to Shut Down Lineage-Plastic Castration-Resistant Prostate Cancer

/in /by

Targeting FOXA1 and FOXA2 in castration-resistant prostate cancer represents a new way of attacking the disease at the level of its lineage “identity” rather than only at the androgen receptor. FOXA1 and FOXA2 belong to a family of pioneer transcription factors. These pioneer transcription factors unlock tightly packed DNA, creating access for other proteins that […]

Read more